Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan
Phase 1 Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Tokyo
-
Chuo-Ku, Tokyo, Japan, 104-0045
- Local Institution
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate
- Life expectancy of at least 3 months
- Eastern Cooperative Oncology Group performance 0-1
Exclusion Criteria:
- Any disorder with dysregulation of glucose homeostasis
- Dumping syndrome
- History of glucose intolerance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: BMS-754807
|
Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To determine the Maximum Tolerated Dose of BMS-754807 based on the Dose Limited Toxicity which observed during the first 28 days
Time Frame: Within the first 28 days
|
Within the first 28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To assess the safety and tolerability
Time Frame: Day 1, 8, 15, 22, 29, thereafter every 2 weeks
|
Day 1, 8, 15, 22, 29, thereafter every 2 weeks
|
|
To establish recommended Phase 2 dose of BMS-754807 when administered orally on a once daily schedule
Time Frame: Day 1, 8, 15, 22, 29, thereafter every 2 weeks
|
Day 1, 8, 15, 22, 29, thereafter every 2 weeks
|
|
To assess the metabolic effect on blood glucose
Time Frame: Day 1, 8, 15, 22, 29, thereafter every 2 weeks
|
Day 1, 8, 15, 22, 29, thereafter every 2 weeks
|
|
To assess the pharmacokinetics of BMS-754807 administered orally on a once daily schedule
Time Frame: Day 1, 8, 15, 22, 29, thereafter every 2 weeks
|
Day 1, 8, 15, 22, 29, thereafter every 2 weeks
|
|
To assess any preliminary evidence of anti-tumor activity
Time Frame: Day 1, 8, 15, 22, 29, thereafter every 2 weeks
|
Day 1, 8, 15, 22, 29, thereafter every 2 weeks
|
|
To explore potential biomarkers of biological response
Time Frame: Day 1, 8, 15, 22, 29, thereafter every 2 weeks
|
Day 1, 8, 15, 22, 29, thereafter every 2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CA191-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.